Soleno Therapeutics (SLNO) Accumulated Expenses (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Accumulated Expenses data on file, last reported at $395000.0 in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 6.62% year-over-year to $395000.0 in Q1 2026; TTM through Mar 2026 was $395000.0, a 6.62% decrease from a year earlier, with the FY2025 full-year figure at $403000.0, down 91.56% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $395000.0, down from $403000.0 in the prior quarter.
• Over the last five years, Accumulated Expenses for SLNO reached as high as $7.2 million in Q3 2025 and fell as low as $395000.0 in Q1 2026.
• Historically, Accumulated Expenses has averaged $2.2 million across 5 years, with a median of $1.3 million in 2022.
• On a YoY basis, Accumulated Expenses climbed as much as 191.62% in 2025 and fell as far as 91.56% in 2025.
• Year by year, Accumulated Expenses stood at $1.7 million in 2022, then jumped by 87.16% to $3.1 million in 2023, then soared by 52.34% to $4.8 million in 2024, then slumped by 91.56% to $403000.0 in 2025, then fell by 1.99% to $395000.0 in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $395000.0 in Q1 2026, $403000.0 in Q4 2025, and $7.2 million in Q3 2025.